Some patients with myelodysplastic syndromes, like acute myeloid leukemia, benefit from a chemotherapy drug called decitabine that stunts cancer growth. But many others are resistant to decatibine’s effects or become resistant over time.
Avalo drops three rare disease assets amid ongoing challenges – Pharmaceutical Technology
Avalo drops three rare disease assets amid ongoing challenges. Credit: Shutterstock / Party people studio. Avalo Therapeutics will divest three compounds in its rare disease
September 13, 2023